Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers

A Randomized, Open, Single-dose, Crossover-design, Phase I Study to Evaluatethe Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers

This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the pharmacokinetics and safety after co-administration of L03RD1 and L03RD2 or administration of L03TD1 in healthy volunteers.

Study Overview

• Status: Active, not recruiting
• Conditions: Type 2 Diabetes Mellitus (T2DM)
• Intervention / Treatment: Drug: L03RD1; Drug: L03RD2; Drug: L03TD1

• Study Type: Interventional
• Enrollment (Estimated): 48
• Phase: Phase 1

Contacts and Locations

Study Locations

• South Korea
  • Seoul, South Korea, 08756
    • H plus Yangji Hostpital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• 1) Subject is between 19 and 55 years of age, inclusive, at the time of screening.
• 2) Subjects who have a BMI between 18.0 and 29.9 kg/m², inclusive, at the time of screening (Body weight ≥50 kg for males, ≥45 kg for females).
• 3) Subjects who have a seated blood pressure at the time of screening between 90 and 139 mmHg systolic and between 60 and 89 mmHg diastolic, inclusive.
• 4) Subjects who do not have clinically significant congenital or chronic diseases and do not have pathological symptoms or findings as a result of internal medical examination. (if necessary, electroencephalography, electrocardiogram, chest and stomach endoscopy, or gastrointestinal radiography, etc.)
• 5) Subjects who are determined by the principal investigator(or the delegated investigator) to be suitable as a study subject based on the results of assessments performed during screening, such as diagnostic tests(e.g., hematology test, blood chemistry test, serology test, urinalysis) and electrocardiogram(ECG) conducted in accordance with the characteristics of the investigational product.

• 6) Subjects or their spouse or partner agree to use a highly effective contraceptive methods* (excluding hormonal agents) to rule out the possibility of pregnancy from the date of first administration of the investigational product until 14 days after the last administration of the investigational product. They also agree not to donate sperm or eggs.

  * Highly effective contraceptive methods: intrauterine device (IUD), bilateral tubal occlusion, vasectomised partner, and sexual abstinence. However, periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception. Furthermore, the simultaneous use of a female condom and a male condom is not permitted.

• 7) Subjects who have voluntarily decided to participate and have signed the informed consent form after receiving sufficient explanation and understanding of the purpose and content of the study, the characteristics of the investigational product, and the expected adverse events.

Exclusion Criteria:

• 1) Subjects who have taken any drug that induces or inhibits drug metabolizing enzymes (e.g. barbiturates) within 1 month prior to the start of the study (date of first administration), or any drug that may affect this study within 10 days prior to the start of the study (date of first administration). (However, based on pharmacokinetic and pharmacodynamic characteristics such as drug interactions with the investigational product or the half-life of concomitant medications, the principal investigator (or the delegated investigator) will determine the subject's eligibility for participation)
• 2) Subjects who participated in another clinical trial or bioequivalence study and received an investigational product within 6 months prior to first administration of investigational product.
• 3) Subjects who have donated whole blood within 8 weeks, donated blood components within 2 weeks, or received a transfusion within 4 weeks prior to first administration of investigational product.
• 4) Subject who have a history of gastrointestinal resection that may affect drug absorption (excluding appendectomy and hernia surgery).

• 5) Subjects who meet any of the following criteria within 1 month prior to first administration of investigational product

  • a. Excessive alcohol consumption

    • More than 21 units/week for males
    • More than 14 units/week for females
    • (1 unit: 50 mL soju, 30 mL whiskey, or 250 mL beer)
  • b. Smoking more than 20 cigarettes per day

• 6) Subjects who have any of the following medical conditions

  • a. Known hypersensitivity to the active ingredient or any component of the investigational product
  • b. Heart failure or a history of heart failure
  • c. Active bladder cancer or history of bladder cancer
  • d. Hepatic impairment
  • e. Severe renal impairment
  • f. Uninvestigated macroscopic hematuria
  • g. Diabetic ketoacidosis, diabetic coma or pre-coma, Type 1 diabetes, or Type 2 diabetes
  • h. Severe infections, perioperative conditions, or moderate trauma
  • i. Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• 7) Subjects who have a history of clinically significant mental illness.
• 8) Subjects who are judged by the principal investigator(or the delegated investigator) to be unsuitable for this clinical trial for reasons other than the above inclusion/exclusion criteria.
• 9) Female subjects who are suspected of being pregnant or breastfeeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: A (L03RD1/L03RD2 -> L03TD1); Administration of 1 tablet of L03RD1 and 2 tablets of L03RD2, and taking 14-day wash-out period, and then administration of 1 table of L03TD1	Drug: L03RD1; 1 tablet of L03RD1; Drug: L03RD2; 2 tablets of L03RD2; Drug: L03TD1; 1 tablet of L03TD1
Experimental: B (L03TD1 -> L03RD1/L03RD2); Administration of 1 table of L03TD1, and taking 14-day wash-out period, and then administration of 1 tablet of L03RD1 and 2 tablets of L03RD2	Drug: L03RD1; 1 tablet of L03RD1; Drug: L03RD2; 2 tablets of L03RD2; Drug: L03TD1; 1 tablet of L03TD1

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
AUCt	Pre-dose, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours
Cmax	Pre-dose, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUCinf	Area under the plasma concentration-time curve from time 0 to infinity	Pre-dose, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours
AUCt/AUCinf		Pre-dose, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours
Tmax	Time of peak plasma concentration	Pre-dose, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours
t1/2	Half-life	Pre-dose, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours
CL/F		Pre-dose, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours

Collaborators and Investigators

• Sponsor: Celltrion

Study record dates

Study Major Dates

• Study Start (Actual): May 9, 2026
• Primary Completion (Estimated): May 24, 2026
• Study Completion (Estimated): June 7, 2026

Study Registration Dates

• First Submitted: April 10, 2026
• First Submitted That Met QC Criteria: April 10, 2026
• First Posted (Actual): April 16, 2026

Study Record Updates

• Last Update Posted (Actual): May 13, 2026
• Last Update Submitted That Met QC Criteria: May 11, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 2
• Other Study ID Numbers: CT-L03-102

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No